Can Ozempic, Mounjaro, and Wegovy Cause Hair Loss?
Quick answer: Hair shedding has been reported during treatment with semaglutide medicines such as Ozempic and Wegovy, as well as with tirzepatide, sold as Mounjaro.
Current Australian medicine information includes hair loss or alopecia for these medicines. Recent research has also found an association between GLP-1 receptor agonists and non-scarring hair loss.
However, this does not mean the medicine is always the direct cause. Rapid or substantial weight loss, reduced food intake, nutritional deficiencies and an underlying hair-loss condition may also contribute.
Do not stop or change a prescribed medicine without speaking to the clinician managing your treatment.
Seeing more hair in the shower, on your pillow or in your brush can be alarming, particularly when it begins after starting a new medicine or losing a significant amount of weight.
The timing and pattern of hair loss provide important clues. Temporary diffuse shedding and progressive pattern hair loss can look similar at first, and some people may experience both conditions at the same time.
What Does Current Research Show?
A 2026 study published in The BMJ used electronic health records to compare adults with type 2 diabetes who started a GLP-1 receptor agonist with people who started two other classes of diabetes medicine.
The study found a:
The absolute risk remained low, and the association was strongest for non-scarring forms of hair loss.
Because this was an observational study and assessed the drug class rather than individual brands, it cannot prove that a particular medicine directly caused the hair loss.[1]
A separate systematic review published in 2026 found that semaglutide and tirzepatide produced the most frequent hair-loss signals in the available studies.
Telogen effluvium and androgenetic alopecia were the most commonly reported patterns. However, the authors also identified important limitations:
- Studies used different definitions of hair loss.
- Many findings came from adverse-event reporting databases.
- Direct effects on the hair follicle have not been proven.
- Individual risk factors were not always adequately recorded.
Australian sources provide another reason to take the concern seriously.
In June 2026, the Therapeutic Goods Administration added alopecia to the adverse-effects information for semaglutide products, including Ozempic and Wegovy. Current Australian medicine information for Ozempic, Wegovy and Mounjaro also includes hair loss.[3–6]
This confirms that hair shedding is a recognised reported event. It does not establish the exact cause of hair loss in an individual patient.
Does Ozempic Cause Hair Loss?
Ozempic contains semaglutide and is registered in Australia for the treatment of type 2 diabetes.
Wegovy contains the same active ingredient but has a different approved use and dosing schedule for chronic weight management. The two brands should not be treated as interchangeable.
Hair loss has been reported during semaglutide treatment. In an individual case, however, it can be difficult to separate the possible effect of the medicine from other factors, including:
- Rapid or substantial weight loss
- Reduced calorie or protein intake
- Nutritional deficiencies
- Illness or physical stress
- Hormonal changes
- An existing tendency towards pattern hair loss
The timing, distribution and progression of the shedding often provide more useful information than the medicine’s brand name alone.
Does Mounjaro Cause Hair Loss?
Mounjaro contains tirzepatide, a medicine that acts as a dual GIP and GLP-1 receptor agonist.
Hair loss appears in current Australian consumer medicine information for Mounjaro.[6]
Tirzepatide can produce substantial weight loss in some people. Therefore, the same potential contributors may apply:
- Rapid changes in body weight
- Eating less because of reduced appetite
- Inadequate protein or energy intake
- Nutritional deficiency
- An underlying hair-loss condition
Current peer-reviewed evidence does not provide a dependable head-to-head answer on whether Mounjaro causes more hair loss than Ozempic or Wegovy.
The dose, amount and speed of weight loss, nutrition, health history and individual susceptibility may all influence what a person experiences.
Why May Hair Shedding Happen During GLP-1 Treatment?
Telogen effluvium after rapid weight loss
Telogen effluvium is a form of diffuse, non-scarring hair shedding that can follow significant physical or emotional stress.
Rapid or substantial weight loss is a recognised trigger.
During telogen effluvium, more hair follicles enter the resting phase at approximately the same time. The increased shedding may not become noticeable until a few months after the original trigger.[7]
This delay can make it difficult to connect the shedding with an earlier period of weight loss, illness, dietary change or medication adjustment.
Reduced energy, protein or nutrient intake
GLP-1 and related medicines can reduce appetite. Some people may then find it difficult to eat enough food overall or maintain adequate protein and micronutrient intake.
A confirmed nutritional deficiency may contribute to shedding. However, symptoms alone cannot identify which nutrient, if any, is involved.
Testing and supplementation should be based on an individual medical assessment rather than a standard supplement plan.
An underlying hair-loss condition
A sudden diffuse shed can make previously subtle androgenetic alopecia more noticeable.
Telogen effluvium and pattern hair loss can also occur together.
If hair density does not recover as expected, or thinning follows a recognisable pattern around the hairline, temples, crown or central part, another diagnosis may need to be considered.
A direct medicine effect remains uncertain
Researchers have not ruled out a direct or indirect biological effect from GLP-1-related treatment.
However, the available evidence cannot establish that these medicines directly damage hair follicles.
For this reason, it is more accurate to describe hair loss as being associated with treatment rather than automatically assuming that the medicine directly caused permanent follicle damage.
Telogen Effluvium vs Pattern Hair Loss
| Feature | Telogen effluvium | Pattern hair loss |
|---|---|---|
| Distribution | Usually diffuse shedding across the scalp | Often affects the hairline, temples, crown or central part |
| Timing | May become noticeable a few months after a trigger | Usually develops gradually, although a sudden shed can make it more obvious |
| What people notice | More loose hair during washing, brushing or styling | Reduced density, finer hairs or progressively increased scalp visibility |
| Likely course | May improve after the trigger settles, although recovery time varies | Can progress without appropriate management |
| Why assessment helps | Helps identify triggers and rule out another condition | Helps clarify the diagnosis and whether medical or surgical options may be appropriate |
How Long Does GLP-1-Related Hair Shedding Last?
There is no single timeline that applies to everyone.
Telogen effluvium often becomes visible several months after a trigger. Improvement may also lag behind stabilisation of weight, health and nutrition.
Shedding may settle before hair density looks better because new hair needs time to grow long enough to become visible. Recovery is therefore generally measured in months rather than weeks.
Some people may recover while continuing their prescribed treatment, but this should not be presented as a guarantee.
Persistent or worsening shedding, incomplete recovery, patchy hair loss or patterned thinning may indicate another contributing condition.
What Should You Do if You Notice Hair Loss?
Speak to your prescriber
Do not stop, pause or change the dose of Ozempic, Wegovy or Mounjaro without medical advice.
Your prescriber can consider:
- Why the medicine was prescribed
- The amount and speed of weight loss
- Gastrointestinal symptoms
- Changes in appetite
- Food and fluid intake
- Other medicines
- Relevant health conditions
Review your food intake
Aim for regular meals or snacks that include a source of protein, together with fruit, vegetables and other foods you tolerate.
If reduced appetite, nausea or another side effect makes it difficult to eat adequately, ask whether advice from an accredited practising dietitian may help.
Record the timeline
Write down:
- When you started the medicine
- When the dose changed
- When your weight began changing
- When the shedding became noticeable
- Whether the loss appears diffuse or concentrated in one area
- Whether you experienced illness, surgery, stress or another health change
Photographs taken in similar lighting and from consistent angles may help document progression.
Seek an individual assessment
A GP or dermatologist can review other possible triggers and decide whether further medical investigation is appropriate.
A hair-restoration consultation may also be useful when patterned or potentially permanent hair loss is suspected.
Bring a list of your medicines, the dates of dose changes, your approximate weight-loss timeline and any recent blood-test results.
Avoid self-prescribing supplements
Iron, zinc, biotin and other supplements are not harmless substitutes for assessment.
Excessive intake can cause health problems. High-dose biotin may also interfere with some laboratory test results.
Treatment should depend on the diagnosis.
A plan for temporary shedding may focus on the underlying trigger and any confirmed nutritional issues. Androgenetic alopecia may require a different medical or surgical discussion.
No single supplement, topical treatment or procedure is suitable for every person taking a GLP-1 medicine.
What Blood Tests May a GP Consider?
There is no universal blood-test panel for every person experiencing hair shedding.
Based on your symptoms, diet, medical history and examination, a GP may consider:
- Full blood count
- Ferritin or iron studies
- Thyroid function
Vitamin B12, folate, vitamin D, zinc or other tests may be relevant when your medical history or symptoms suggest a specific deficiency or health condition.
Broad, untargeted testing is not routinely supported when the medical history and review of systems do not suggest another condition.
Targeted tests may still be appropriate based on symptoms, diet, medical history and examination. The final choice of tests should remain with the treating clinician.[9]
When Should You Seek Medical Advice?
Arrange an assessment sooner if you notice:
- Patchy hair loss or smooth bald areas
- Loss of eyebrow or eyelash hair
- Scalp pain, redness, marked itching or scaling
- Signs of scalp scarring
- Rapidly worsening thinning
- A clear change at the hairline, temples, crown or central part
- Shedding that continues after the likely trigger has settled
- Hair density that does not begin to recover
- Fatigue, weakness, menstrual changes or other unexplained symptoms
- Difficulty maintaining adequate food or fluid intake because of treatment side effects
Can You Have a Hair Transplant While Taking Ozempic or Mounjaro?
A hair transplant redistributes suitable donor follicles to areas affected by permanent hair loss.
It does not treat active telogen effluvium.
If diffuse shedding is still changing, it may be difficult to determine the person’s actual pattern of permanent hair loss or plan an appropriate transplant.
Assessment and a period of stability may therefore be required before surgery is considered.
When may a hair transplant discussion be premature?
Surgery may be premature when:
- Hair shedding is still increasing.
- Body weight is changing rapidly.
- The cause of the hair loss remains unclear.
- The visible pattern has not stabilised.
- The donor area has not been properly assessed.
- The person is struggling to maintain adequate nutrition or hydration.
There is no single waiting period that suits every patient.
Serial photographs, medical history and the clinical course are generally more useful than choosing an arbitrary number of months.
What should be clear before planning surgery?
Before planning a hair transplant, the consultation should establish:
- Whether permanent pattern hair loss is present
- Whether temporary diffuse shedding is also occurring
- Whether the donor area is suitable
- How future hair loss may progress
- Whether the person’s health is stable
- Whether medication and weight changes make the proposed timing appropriate
This helps prevent temporary shedding from being treated as though it were permanent baldness.
Tell the treating team about every prescription medicine you use, including Ozempic, Wegovy or Mounjaro.
Australian guidance for procedures involving anaesthesia or sedation does not recommend routine pre-procedure cessation of GLP-1 or dual GIP/GLP-1 medicines.
Instead, it recommends individual risk assessment and appropriate preparation. This may include a 24-hour clear-fluid diet followed by standard fasting for relevant patients.[8]
The exact instructions depend on:
- The planned procedure
- The type of anaesthesia or sedation
- The medicine being used
- Gastrointestinal symptoms
- The patient’s medical circumstances
Always follow the instructions provided by the prescriber, surgeon and anaesthesia team.
How to Prepare for a Hair-Loss Consultation
The following information can make your consultation more useful:
- The name of the medicine
- The date treatment began
- The current dose
- Dates of any dose changes
- An approximate timeline of weight changes
- When the shedding became noticeable
- Photographs taken under similar lighting
- A list of other medicines and supplements
- Details of recent illnesses, surgery or major health changes
- Recent blood-test results
- Relevant family history of hair loss
Frequently Asked Questions
Is hair loss from Ozempic permanent?
It may not be permanent when the main problem is telogen effluvium.
However, recovery varies, and another hair-loss condition may also be present. Ongoing, patchy or patterned loss should be assessed rather than automatically assumed to be temporary.
Should I stop Ozempic, Mounjaro or Wegovy if my hair is falling out?
Do not stop or change a prescribed medicine without speaking to the clinician who manages your treatment.
They can consider the benefits of the medicine, your symptoms and other health factors before deciding whether any change is appropriate.
How soon can hair shedding start?
Telogen effluvium often becomes noticeable a few months after a trigger.
The relevant trigger may be weight loss, reduced food intake, illness, a dose change or another event. Reviewing the full timeline is therefore important.
Does Mounjaro cause more hair loss than Ozempic?
Current peer-reviewed evidence does not provide a dependable head-to-head comparison.
The amount and speed of weight loss, nutrition, dose, health history and individual susceptibility may all influence risk.
Will my hair grow back after GLP-1-related shedding?
Hair may regrow when temporary shedding settles and the underlying trigger has resolved.
However, visible density takes time to improve. Recovery should not be guaranteed, particularly when pattern hair loss or another condition is also present.
Can I have a hair transplant while taking a GLP-1 medicine?
Possibly, but the diagnosis and timing are important.
Active diffuse shedding should be assessed first, and the surgical team must know about the medicine. Preparation for sedation or anaesthesia should follow the instructions provided by the treating team.
Discuss Your Hair-Loss Concerns
Bijan Clinic in Auburn, Sydney offers a free initial consultation.
If you have noticed hair shedding while using Ozempic, Mounjaro, Wegovy or another weight-management medicine, a consultation provides an opportunity to discuss your concerns and determine whether further medical assessment or a hair-restoration discussion may be appropriate.
Book a free initial consultationor call +61 450 347 491 .
Medical information notice: This article provides general information and does not replace advice from your doctor, pharmacist, dietitian or another qualified health professional. Do not start, stop or change a prescribed medicine based on this article.
References
- Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes — The BMJ
- GLP-1 therapies and hair loss: a systematic review of current evidence and implications for counseling — Science Progress
- Product Information safety updates — Therapeutic Goods Administration
- Ozempic Australian medicine information
- Wegovy Australian medicine information
- Mounjaro Australian medicine information
- Telogen effluvium — DermNet
- Clinical recommendations for patients taking GLP-1 medicines before anaesthesia or sedation — ANZCA
- Neubauer ZJK, Lipner SR. Broad laboratory testing does not show utility for telogen effluvium: A retrospective analysis of 22-million laboratory results using TriNetX . JAAD International. 2026;25:81–83. doi:10.1016/j.jdin.2025.12.013.